Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center experience

İLHAN O., TOPÇUOĞLU P., Arat M., Soydan E. A., YÜKSEL M., ARSLAN Ö., ...Daha Fazla

Turkish Journal of Hematology, cilt.25, sa.2, ss.87-93, 2008 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 2
  • Basım Tarihi: 2008
  • Dergi Adı: Turkish Journal of Hematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.87-93
  • Anahtar Kelimeler: Allogeneic transplantation, AML, Graft versus host disease, HLA-identical sibling donor, Stem cell source
  • Ankara Üniversitesi Adresli: Evet

Özet

We retrospectively analyzed the impact of pre- and post-transplant variables on the outcome of transplantation in 145 consecutive patients with acute myeloblastic leukemia (AML) allografted from their HLA-identical siblings in our single center cohort. Results: The stem cell sourcme used was bone marrow (BR) (36.6%) or peripheral blood (PB) (63.4%). Both neutrophil and platelet engraftments were observed on the median 14th day. Engraftment was faster in the PB group than in the BM group (p<0.0001). Severe acute graft versus host disease (aGvHD) was observed in 27.9% of the patients while chronic (c)GvHD developed in 61.2%. The use of PB was associated with more severe aGvHD. Estimated leukemia-free survival (LFS) and overall survival (OS) at 10 years were 43.4%±5.2% and 52.7%±4.6%, respectively. Conclusion: Both in univariate and multivariate analyses for LFS and OS, remission status at transplant and the presence of aGvHD were independent risk factors.